Lesinurad

CHEMBL2105720 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
404.3 g/mol
LogP
4.7
Phase
4

A uric acid transporter inhibitor for gout.

Molekularmasse

404,3000 g/mol

LogP

4,70

TPSA

93,30 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12

InChI

InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)

Molecular Formula

C17H14BrN3O2S

HBD / HBA

1 / 5

Rotierbare Bindungen

5

Schwere Atome

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A uric acid transporter inhibitor for gout.

Yes, Lesinurad is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105720. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 53465279. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.